Search clinical trials for: a proliferation-inducing ligand

Total 494777 results

Regeneron Pharmaceuticals

Not yet recruiting

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

Melanoma | Advanced Solid Tumors | Clear-Cell Renal-Cell Carcinoma (ccRCC)
GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer

United States
University Hospital, Basel, Switzerland

Not yet recruiting

Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (PROGNOSTICS)

Castration-resistant Prostate Cancer

Switzerland
Merck Sharp & Dohme LLC

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms

Israel, United States, Taiwan
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)

Renal Cell Carcinoma

United States, Australia, Canada, Chile, Taiwan
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005)

Bladder Cancer

Canada, Germany, Australia, United States, Poland, Spain, Chile, France, Sweden, Italy
Assiut University

Not yet recruiting

Effect of Intravenous Nalbuphine and Magnesium Sulfate on Emergence Agitation in Pediatric

Emergence Delirium
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
National Cancer Institute (NCI)

Recruiting

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Small Cell Carcinoma of the Bladder | High Grade Neuroendocrine Tumors of the Urinary Tract

United States
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
Jonsson Comprehensive Cancer Center

Not yet recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Prostate Carcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Sichuan University

Recruiting

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Lung Cancer | Extensive-stage Small-cell Lung Cancer

China
Pharmtechnology LLC

Recruiting

Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Mayo Clinic

Recruiting

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Leucid Bio

Recruiting

LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours. (AERIAL)

Tumor, Solid

United Kingdom
Guangdong Provincial People's Hospital
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Recruiting

A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors (68Ga-GPFAPI)

Cancer | Metastatic Cancer | Malignant Neoplasm | Tumors

China
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)

China, Australia, United States, Turkey, Chile, Taiwan, Denmark, France, Spain, Argentina, Italy, Netherlands, Thailand
National Cancer Institute (NCI)

Not yet recruiting

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Squamous Cell Carcinoma of the Penis | Renal Medullary Carcinoma | Squamous Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Urinary Tract | Squamous Cell Carcinoma of the Urinary Tract | Primary Adenocarcinoma of the Bladder | Primary Adenocarcinoma...

United States
IRCCS National Neurological Institute "C. Mondino...

Recruiting

HD-EEG Connectivity Changes in Migraine Patients Undergoing Treatment With Anti-CGRP mAbs

Migraine Disorders | Chronic Migraine | Episodic Migraine

Italy
University of Washington
Novartis; Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Jonsson Comprehensive Cancer Center
Janssen Scientific Affairs, LLC

Recruiting

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (HEATWAVE)

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Non-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Japan
National Cancer Institute (NCI)

Not yet recruiting

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Testicular Germ Cell Tumors

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-3475A (Pembrolizumab Formulated With MK-5180) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Squamous Cell Carcinoma

Japan
Merck Sharp & Dohme LLC

Recruiting

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Solid Tumor | Endometrial Cancer | Cutaneous Squamous Cell Carcinoma

Canada, Australia, Taiwan, Malaysia, United States, Netherlands, Turkey, France
AstraZeneca

Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung

United States
Qian Chu
Akeso Pharmaceuticals, Inc.

Recruiting

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative (ACHELOUS)

Carcinoma, Non-Small-Cell Lung

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant Therapy

Magnetic Resonance Imaging | Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy

China
Pharmtechnology LLC

Recruiting

Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Merck Sharp & Dohme LLC

Recruiting

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid Tumors | Metastatic Solid Tumors

Canada, Switzerland, United States
Coherent Biopharma (Hefei) Co., Ltd.

Recruiting

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Cancer, Breast | Cancer of Pancreas | Cancer Colorectal | Cancer, Lung | Cancer of Esophagus

China, United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States, Malaysia, Australia, Georgia, Israel
First Affiliated Hospital, Sun Yat-Sen University
Nanfang Hospital of Southern Medical University; Sun Yat-Sen Memorial Hospital... and other collaborators

Not yet recruiting

BAFF/APRIL in Kidney Transplant Rejection Risk Assessment (BA-TRAP)

Kidney Transplantation | Kidney Transplant Rejection

China
Efferon JSC
Ligand Research, LLC

Recruiting

Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Sepsis (LASSONEO)

Sepsis | Septic Shock

Russian Federation
Jiangsu Healthy Life Innovation Medical Technology...

Not yet recruiting

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Non-small Cell Lung Cancer (NSCLC)

China
Merck Sharp & Dohme LLC
Gilead Sciences

Recruiting

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Carcinoma, Non-Small-Cell Lung

China, Poland, Latvia, United States, Taiwan, Australia, Turkey, Germany, Israel, Korea, Republic of, Estonia, Romania, Chile, Italy, Brazil, Greece, Philippines, Canada, Japan, Malaysia, United Kingdom, Lithuania, Thailand, Peru
Johns Hopkins University
United States Department of Defense

Not yet recruiting

Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS

ALS
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

Advanced or Metastatic Solid Tumors

Canada, Switzerland, United States
Sohag University

Not yet recruiting

Expression of Programmed Death Ligand-1 (PD-L1) in Nasopharyngeal and Hyypopharyngeal Carcinoma

Nasopharyngeal and Hypopharyngeal Carcinoma

Egypt
Esraa Mostafa Ahmed Abdel Aal

Not yet recruiting

Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure (seizure)

Localization-Related (Focal) (Partial) Idiopathic Epilepsy and Epileptic Syndromes With Seizures of Localized Onset | TRAIL: Tumor Necrosis Factor Related Apoptosis Inducing Ligand MCP-2 | MCP-2: Monocyte Chemo-attractant Protein-2
Regeneron Pharmaceuticals
BioNTech SE

Recruiting

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Advanced Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, Georgia, Taiwan, Germany, Turkey
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Hodgkin Lymphoma

Australia, Israel, Korea, Republic of, Spain, Poland, Sweden, United Kingdom, Turkey, China, United States, Brazil, Germany, Belgium, France, Switzerland, Canada, Czechia, Chile, Argentina
Merck Sharp & Dohme LLC

Recruiting

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Renal Cell Carcinoma

United States, Australia, Israel
Sohag University

Not yet recruiting

Expression of Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PDL-1) in Acute Lymphoblastic Leukemia in Pediatric

Acute Lymphoblastic Leukemia in Pediatric

Egypt
Peking University

Not yet recruiting

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Advanced or Metastatic Solid Tumors

United States, Canada, Israel, Netherlands
Odense University Hospital
Aarhus University Hospital; University of Copenhagen; University Hospital Ostrava

Recruiting

Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction

Quality of Life | Multiple Sclerosis | Sexual Dysfunction | Bowel Dysfunction | Neurogenic Dysfunction of the Urinary Bladder | Sacral Neuromodulation

Denmark
Merck Sharp & Dohme LLC

Recruiting

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Esophageal Squamous Cell Carcinoma (ESCC)

Japan, Korea, Republic of, Taiwan, Thailand, France, Turkey, Italy, Switzerland, Brazil, Singapore, Germany, Chile, Norway

Search clinical trials for: a proliferation-inducing ligand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations